The Q-Plex SARS-CoV-2 Human IgG (4-Plex) ELISA tests for IgG antibodies to either the SARS-CoV-2 S1 protein or the SARS-CoV-2 S2 protein. Our validation studies identified measurable improvement in clinical performance when results from the S1 and S2 assays are considered together rather than single assays (see assay validation data below). Quansys recommends that a sample should only be considered positive for the presence of SARS-CoV-2 reactive IgGs when antibodies reactive to both S1 and S2 are detected.
Negative samples, collected prior to August 2019, and known positive samples collected from individuals who tested positive for COVID-19 on a molecular test at least 14 days prior to sample collection were used to determine clinical sensitivity and specificity.
The Q-Plex SARS-CoV-2 Human IgG (4-plex) is a qualitative chemiluminescent assay (ELISA) allowing concurrent measurement of human IgG antibodies to SARS-CoV-2 S1 and SARS-CoV-2 S2 proteins in serum and plasma samples.
The Q-Plex SARS-CoV-2 Human IgG (4-plex) has been authorized by FDA under a EUA for use by high complexity CLIA labs.
Sensitive, reproducible, and convenient 96-well format requiring low sample volumes
Processing
All Quansys Q-Plex™ Multiplex and Singleplex assays require the use of the Q-View™ software to read and interpret the test results. A fully-functional, free trial version of the software is available to download, install, and use to analyze your first kit(s). At the end of the trial period, a purchased license is required to continue the use of the Q-View software.
Q-Plex arrays are developed and optimized to work with Q-View imagers.